Advanced Distance-Resolved Evaluation of the Perienhancing Tumor Areas with FLAIR Hyperintensity Indicates Different ADC Profiles by MGMT Promoter Methylation Status in Glioblastoma

References

1. 1.↵
   1. Louis DN,
   2. Perry A,
   3. Wesseling P, et al

   . The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol 2021;23:1231–51 doi:10.1093/neuonc/noab106 pmid:34185076

   CrossRefPubMed
2. 2.↵
   1. Esteller M,
   2. Garcia-Foncillas J,
   3. Andion E, et al

   . Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000;343:1350–54 doi:10.1056/NEJM200011093431901 pmid:11070098

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Hegi ME,
   2. Diserens AC,
   3. Gorlia T, et al

   . MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997–1003 doi:10.1056/NEJMoa043331 pmid:15758010

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Malmstrom A,
   2. Gronberg BH,
   3. Marosi C

   ; Nordic Clinical Brain Tumour Study Group (NCBTSG), et al. Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet Oncol 2012;13:916–26 doi:10.1016/S1470-2045(12)70265-6 pmid:22877848

   CrossRefPubMedWeb of Science
5. 5.↵
   1. Stupp R,
   2. Hegi ME,
   3. Mason WP

   ; National Cancer Institute of Canada Clinical Trials Group, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009;10:459–66 doi:10.1016/S1470-2045(09)70025-7 pmid:19269895

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Weller M,
   2. van den Bent M,
   3. Hopkins K

   ; European Association for Neuro-Oncology (EANO) Task Force on Malignant Glioma, et al. EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma. Lancet Oncol 2014;15:e395–403 doi:10.1016/S1470-2045(14)70011-7 pmid:25079102

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Kong DS,
   2. Kim ST,
   3. Kim EH, et al

   . Diagnostic dilemma of pseudoprogression in the treatment of newly diagnosed glioblastomas: the role of assessing relative cerebral blood flow volume and oxygen-6-methylguanine-DNA methyltransferase promoter methylation status. AJNR Am J Neuroradiol 2011;32:382–87 doi:10.3174/ajnr.A2286 pmid:21252041

   Abstract/FREE Full Text
8. 8.↵
   1. Brandes AA,
   2. Franceschi E,
   3. Tosoni A, et al

   . Methylguanine DNA-methyltransferase methylation status can change between first surgery for newly diagnosed glioblastoma and second surgery for recurrence: clinical implications. Neuro Oncol 2010;12:283–88 doi:10.1093/neuonc/nop050 pmid:20167816

   CrossRefPubMed
9. 9.↵
   1. Jung TY,
   2. Jung S,
   3. Moon KS, et al

   . Changes of the O6-methylguanine-DNA methyltransferase promoter methylation and MGMT protein expression after adjuvant treatment in glioblastoma. Oncol Rep 2010;23:1269–76doi:10.3892/or_00000760

   CrossRefPubMed
10. 10.↵
    1. Dong Z,
    2. Cui H

    . Epigenetic modulation of metabolism in glioblastoma. Semin Cancer Biol 2019;57:45–51 doi:10.1016/j.semcancer.2018.09.002 pmid:30205139

    CrossRefPubMed
11. 11.↵
    1. De Vleeschouwer S

    1. Li P,
    2. Wu M

    . Epigenetic mechanisms of glioblastoma. In: De Vleeschouwer S, ed. Glioblastoma. Brisbane (AU): Codon Publications; 2017
12. 12.↵
    1. Uddin MS,
    2. Mamun AA,
    3. Alghamdi BS, et al

    . Epigenetics of glioblastoma multiforme: from molecular mechanisms to therapeutic approaches. Semin Cancer Biol 2022;83:100–20 doi:10.1016/j.semcancer.2020.12.015 pmid:33370605

    CrossRefPubMed
13. 13.↵
    1. Lemee JM,
    2. Clavreul A,
    3. Aubry M, et al

    . Characterizing the peritumoral brain zone in glioblastoma: a multidisciplinary analysis. J Neurooncol 2015;122:53–61 doi:10.1007/s11060-014-1695-8 pmid:25559687

    CrossRefPubMed
14. 14.↵
    1. Lemee JM,
    2. Clavreul A,
    3. Menei P

    . Intratumoral heterogeneity in glioblastoma: don’t forget the peritumoral brain zone. Neuro Oncol 2015;17:1322–32 doi:10.1093/neuonc/nov119 pmid:26203067

    CrossRefPubMed
15. 15.↵
    1. Giambra M,
    2. Di Cristofori A,
    3. Valtorta S, et al

    . The peritumoral brain zone in glioblastoma: where we are and where we are going. J Neurosci Res 2023;101:199–216 doi:10.1002/jnr.25134 pmid:36300592

    CrossRefPubMed
16. 16.↵
    1. Artzi M,
    2. Bokstein F,
    3. Blumenthal DT, et al

    . Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: a longitudinal MRI study. Eur J Radiology 2014;83:1250–56 doi:10.1016/j.ejrad.2014.03.026 pmid:24809637

    CrossRefPubMed
17. 17.↵
    1. Martin-Noguerol T,
    2. Mohan S,
    3. Santos-Armentia E, et al

    . Advanced MRI assessment of non-enhancing peritumoral signal abnormality in brain lesions. Eur J Radiology 2021;143:109900 doi:10.1016/j.ejrad.2021.109900 pmid:34412007

    CrossRefPubMed
18. 18.↵
    1. Brandes AA,
    2. Tosoni A,
    3. Franceschi E, et al

    . Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation with MGMT promoter methylation status. J Clin Oncol 2009;27:1275–79 doi:10.1200/JCO.2008.19.4969 pmid:19188675

    Abstract/FREE Full Text
19. 19.↵
    1. Chamberlain MC

    . Radiographic patterns of relapse in glioblastoma. J Neurooncol 2011;101:319–23 doi:10.1007/s11060-010-0251-4 pmid:21052776

    CrossRefPubMed
20. 20.↵
    1. Chang PD,
    2. Malone HR,
    3. Bowden SG, et al

    . A multiparametric model for mapping cellularity in glioblastoma using radiographically localized biopsies. AJNR Am J Neuroradiol 2017;38:890–98 doi:10.3174/ajnr.A5112 pmid:28255030

    Abstract/FREE Full Text
21. 21.↵
    1. Baehring JM,
    2. Fulbright RK

    . Diffusion-weighted MRI in neuro-oncology. CNS Oncol 2012;1:155–67 doi:10.2217/cns.12.28 pmid:25057865

    CrossRefPubMed
22. 22.↵
    1. Cha S

    . Update on brain tumor imaging: from anatomy to physiology. AJNR Am J Neuroradiol 2006;27:475–87 pmid:16551981

    PubMedWeb of Science
23. 23.↵
    1. Moon WJ,
    2. Choi JW,
    3. Roh HG, et al

    . Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging. Neuroradiology 2012;54:555–63 doi:10.1007/s00234-011-0947-y pmid:21833736

    CrossRefPubMed
24. 24.↵
    1. Murakami R,
    2. Sugahara T,
    3. Nakamura H, et al

    . Malignant supratentorial astrocytoma treated with postoperative radiation therapy: prognostic value of pretreatment quantitative diffusion-weighted MR imaging. Radiology 2007;243:493–99 doi:10.1148/radiol.2432060450 pmid:17356177

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Sadeghi N,
    2. D’Haene N,
    3. Decaestecker C, et al

    . Apparent diffusion coefficient and cerebral blood volume in brain gliomas: relation to tumor cell density and tumor microvessel density based on stereotactic biopsies. AJNR Am J Neuroradiol 2008;29:476–82 doi:10.3174/ajnr.A0851

    CrossRefPubMed
26. 26.↵
    1. Yamasaki F,
    2. Kurisu K,
    3. Satoh K, et al

    . Apparent diffusion coefficient of human brain tumors at MR imaging. Radiology 2005;235:985–91 doi:10.1148/radiol.2353031338 pmid:15833979

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Barajas RF Jr.,
    2. Hodgson JG,
    3. Chang JS, et al

    . Glioblastoma multiforme regional genetic and cellular expression patterns: influence on anatomic and physiologic MR imaging. Radiology 2010;254:564–76 doi:10.1148/radiol.09090663 pmid:20093527

    CrossRefPubMedWeb of Science
28. 28.↵
    1. Sugahara T,
    2. Korogi Y,
    3. Kochi M, et al

    . Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging 1999;9:53–60 doi:10.1002/(SICI)1522-2586(199901)9:1<53::AID-JMRI7>3.0.CO;2-2

    CrossRefPubMedWeb of Science
29. 29.↵
    1. Higano S,
    2. Yun X,
    3. Kumabe T, et al

    . Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 2006;241:839–46 doi:10.1148/radiol.2413051276 pmid:17032910

    CrossRefPubMedWeb of Science
30. 30.↵
    1. Pope WB,
    2. Lai A,
    3. Mehta R, et al

    . Apparent diffusion coefficient histogram analysis stratifies progression-free survival in newly diagnosed bevacizumab-treated glioblastoma. AJNR Am J Neuroradiol 2011;32:882–89 doi:10.3174/ajnr.A2385 pmid:21330401

    Abstract/FREE Full Text
31. 31.↵
    1. Pope WB,
    2. Qiao XJ,
    3. Kim HJ, et al

    . Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol 2012;108:491–98 doi:10.1007/s11060-012-0847-y pmid:22426926

    CrossRefPubMed
32. 32.↵
    1. Saksena S,
    2. Jain R,
    3. Narang J, et al

    . Predicting survival in glioblastomas using diffusion tensor imaging metrics. J Magn Reson Imaging 2010;32:788–95 doi:10.1002/jmri.22304 pmid:20882608

    CrossRefPubMed
33. 33.↵
    1. Wen QT,
    2. Jalilian L,
    3. Lupo JM, et al

    . Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab. J Neurooncol 2015;121:331–39 doi:10.1007/s11060-014-1636-6 pmid:25351579

    CrossRefPubMed
34. 34.↵
    1. Zulfiqar M,
    2. Yousem DM,
    3. Lai H

    . ADC values and prognosis of malignant astrocytomas: does lower ADC predict a worse prognosis independent of grade of tumor? A meta-analysis. AJR Am J Roentgenol 2013;200:624–29 doi:10.2214/AJR.12.8679 pmid:23436853

    CrossRefPubMed
35. 35.↵
    1. Choi HJ,
    2. Choi SH,
    3. You SH, et al

    . MGMT promoter methylation status in initial and recurrent glioblastoma: correlation study with DWI and DSC PWI features. AJNR Am J Neuroradiol 2021;42:853–60 doi:10.3174/ajnr.A7004 pmid:33632732

    Abstract/FREE Full Text
36. 36.↵
    1. Choi YS,
    2. Ahn SS,
    3. Kim DW, et al

    . Incremental prognostic value of ADC histogram analysis over MGMT promoter methylation status in patients with glioblastoma. Radiology 2016;281:175–84 doi:10.1148/radiol.2016151913 pmid:27120357

    CrossRefPubMed
37. 37.↵
    1. Gupta A,
    2. Prager A,
    3. Young RJ, et al

    . Diffusion-weighted MR imaging and MGMT methylation status in glioblastoma: a reappraisal of the role of preoperative quantitative ADC measurements. AJNR Am J Neuroradiol 2013;34:E10–11 doi:10.3174/ajnr.A3467 pmid:23275590

    FREE Full Text
38. 38.↵
    1. Kanazawa T,
    2. Minami Y,
    3. Jinzaki M, et al

    . Predictive markers for MGMT promoter methylation in glioblastomas. Neurosurg Rev 2019;42:867–76 doi:10.1007/s10143-018-01061-5 pmid:30673883

    CrossRefPubMed
39. 39.↵
    1. Ladenhauf VK,
    2. Galijasevic M,
    3. Kerschbaumer J, et al

    . Peritumoral ADC values correlate with the MGMT methylation status in patients with glioblastoma. Cancers (Basel) 2023;15:15 doi:10.3390/cancers15051384

    CrossRef
40. 40.↵
    1. Romano A,
    2. Calabria LF,
    3. Tavanti F, et al

    . Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status. Eur Radiology 2013;23:513–20 doi:10.1007/s00330-012-2601-4 pmid:22875158

    CrossRefPubMed
41. 41.↵
    1. Rundle-Thiele D,
    2. Day B,
    3. Stringer B, et al

    . Using the apparent diffusion coefficient to identifying MGMT promoter methylation status early in glioblastoma: importance of analytical method. J Med Radiat Sci 2015;62:92–98 doi:10.1002/jmrs.103 pmid:26229673

    CrossRefPubMed
42. 42.↵
    1. Auer TA,
    2. Kern M,
    3. Fehrenbach U, et al

    . T2 mapping of the peritumoral infiltration zone of glioblastoma and anaplastic astrocytoma. Neuroradiol J 2021;34:392–400 doi:10.1177/1971400921989325 pmid:33573473

    CrossRefPubMed
43. 43.↵
    1. Blystad I,
    2. Warntjes JBM,
    3. Smedby O, et al

    . Quantitative MRI for analysis of peritumoral edema in malignant gliomas. PLoS One 2017;12:e0177135 doi:10.1371/journal.pone.0177135 pmid:28542553

    CrossRefPubMed
44. 44.↵
    1. Bady P,
    2. Delorenzi M,
    3. Hegi ME

    . Sensitivity analysis of the MGMT-STP27 model and impact of genetic and epigenetic context to predict the MGMT methylation status in gliomas and other tumors. J Mol Diagn 2016;18:350–61 doi:10.1016/j.jmoldx.2015.11.009 pmid:26927331

    CrossRefPubMed
45. 45.↵
    1. Bossuyt PM,
    2. Reitsma JB,
    3. Bruns DE

    ; STARD Group, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. Radiology 2015;277:826–32 doi:10.1148/radiol.2015151516 pmid:26509226

    CrossRefPubMed
46. 46.↵
    1. Garyfallidis E,
    2. Brett M,
    3. Amirbekian B

    ; Dipy Contributors, et al. Dipy, a library for the analysis of diffusion MRI data. Front Neuroinform 2014;8:8 doi:10.3389/fninf.2014.00008 pmid:24600385

    CrossRefPubMed
47. 47.↵
    1. Ronneberger O,
    2. Fischer P,
    3. Brox T

    . U-Net: convolutional networks for biomedical image segmentation. Lect Notes Comput Sc 2015;9351:234–41

    CrossRef
48. 48.↵
    1. Menze BH,
    2. Jakab A,
    3. Bauer S, et al

    . The Multimodal Brain Tumor Image Segmentation Benchmark (BRATS). IEEE Trans Med Imaging 2015;34:1993–2024 doi:10.1109/TMI.2014.2377694 pmid:25494501

    CrossRefPubMed
49. 49.↵
    1. Fedorov A,
    2. Beichel R,
    3. Kalpathy-Cramer J, et al

    . 3D slicer as an image computing platform for the Quantitative Imaging Network. Magn Reson Imaging 2012;30:1323–41 doi:10.1016/j.MRI.2012.05.001 pmid:22770690

    CrossRefPubMedWeb of Science
50. 50.↵
    1. Schroeder W,
    2. Martin K,
    3. Lorensen B

    . The Visualization Toolkit: Object-Oriented Approach to 3D Graphics. 4th ed. Kitware, Inc; 2006.
51. 51.↵
    1. Ellingson BM,
    2. Cloughesy TF,
    3. Pope WB, et al

    . Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas. Neuroimage 2012;59:908–16 doi:10.1016/j.neuroimage.2011.09.076 pmid:22001163

    CrossRefPubMedWeb of Science